[{"breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.3 Anti-infective eye preparations", "11.3.1 Antibacterials", "TOBRAMYCIN"], "indications": "Indications\u00a0\n(From 11.3.1 Antibacterials: British National Formulary)\n11.3.1 Antibacterials", "name": "TOBRAMYCIN", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/213676.htm", "doses": ["adult and child over 1 year, apply twice daily for 6\u20138 days;\r\nin severe infection, apply 4 times daily on the first day, then twice\r\ndaily for 5\u20137 days"]}, {"indications": "Indications\u00a0see under Gentamicin and notes above", "name": "TOBRAMYCIN Inhalation", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.4 Aminoglycosides", "TOBRAMYCIN", "Inhalation"], "cautions": "Cautions\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nCautions\u00a0The main side-effects of the aminoglycosides are dose-related, therefore, care must be taken with dosage, and, whenever possible, parenteral treatment should not exceed 7 days. Renal function should be assessed before starting an aminoglycoside and during treatment. If possible, dehydration should be corrected before starting an aminoglycoside. Auditory and vestibular function should also be monitored during treatment. In order to optimise the dose and avoid toxicity, serum-aminoglycoside concentrations should be monitored in patients receiving parenteral aminoglycosides (see also Serum Concentrations). Ototoxicity and nephrotoxicity occur most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.Aminoglycosides should be used with caution in those with conditions characterised by muscular weakness (avoid in myasthenia gravis). Aminoglycosides should preferably not be given with potentially ototoxic diuretics (e.g. furosemide); if concurrent use is unavoidable administration of the aminoglycoside and of the diuretic should be separated by as long a period as practicable. Interactions: Appendix 1 (aminoglycosides); interactions: Appendix 1 (aminoglycosides)Specific cautions for inhaled treatment\u00a0Other\r\ninhaled drugs should be administered before tobramycin. Measure lung\r\nfunction before and after initial dose of tobramycin and monitor for\r\nbronchospasm; if bronchospasm occurs in a patient not using a bronchodilator,\r\nrepeat test using bronchodilator. Monitor renal function before treatment\r\nand then annually. Severe haemoptysis\u2014risk of further haemorrhage.", "side-effects": "Side-effects\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nSide-effects\u00a0The important side-effects of the aminoglycosides are nephrotoxicity and irreversible ototoxicity (including vestibular and auditory damage). Rash occurs commonly with streptomycin, but less frequently with the other aminoglycosides. Rare side-effects include nausea, vomiting, antibiotic-associated colitis, peripheral neuropathy, electrolyte disturbances (notably hypomagnesaemia on prolonged therapy, but also hypocalcaemia and hypokalaemia), and stomatitis. Side-effects reported very rarely include blood disorders and CNS effects (including headache, encephalopathy, and convulsions). Aminoglycosides may impair neuromuscular transmission; large doses given during surgery have been responsible for a transient myasthenic syndrome in patients with normal neuromuscular function.; on inhalation, cough (more frequent by inhalation of powder),\r\nbronchospasm (see Cautions), dysphonia, taste disturbances, pharyngitis,\r\nmouth ulcers, salivary hypersecretion, laryngitis, haemoptysis, epistaxis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/85440.htm", "doses": ["To avoid excessive dosage in obese patients, use ideal\r\nweight for height to calculate parenteral dose and monitor serum-tobramycin\r\nconcentration closely", "By intramuscular injection or by slow intravenous injection or by intravenous infusion, 3\u00a0mg/kg daily in divided\r\ndoses every 8 hours, see also notes above; in severe infections up\r\nto 5\u00a0mg/kg daily in divided doses every 6\u20138 hours (reduced to 3\u00a0mg/kg\r\nas soon as clinically indicated); child under 18 years see BNF for Children", "Urinary-tract infection, by intramuscular injection, 2\u20133\u00a0mg/kg daily as a single dose", "One-hour (\u2018peak\u2019) serum concentration should\r\nnot exceed 10\u00a0mg/litre; pre-dose (\u2018trough\u2019) concentration should be\r\nless than 2\u00a0mg/litre", "Chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis, by inhalation\r\nof nebulised solution, adult and child over 6 years, 300\u00a0mg every\r\n12 hours for 28 days, subsequent courses repeated after 28-day interval\r\nwithout tobramycin nebuliser solution", "By inhalation of powder, adult and child over 6 years, 112\u00a0mg every\r\n12 hours for 28 days, subsequent courses repeated after 28-day interval\r\nwithout tobramycin inhalation powder", "Name[Tobi\u00ae (Novartis) ] Nebuliser solution, tobramycin 60\u00a0mg/mL, net price 56 \u00d7 5-mL (300-mg) unit = \u00a31187.20\nPodhaler (dry powder for inhalation),\r\ntobramycin 28\u00a0mg/capsule, net price 56-cap pack (with Tobi\u00ae Podhaler device) = \u00a3447.50, 224-cap pack (with\r\n5 Tobi\u00ae Podhaler devices) =\r\n\u00a31790.00. Counselling, administration"], "pregnancy": "Pregnancy\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nPregnancy\u00a0There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin (section 5.1.9). The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential (if given, serum-aminoglycoside concentration monitoring is essential)."}, {"indications": "Indications\u00a0see under Gentamicin and notes above", "name": "TOBRAMYCIN - AMINOGLYCOSIDES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.4 Aminoglycosides", "TOBRAMYCIN"], "cautions": "Cautions\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nCautions\u00a0The main side-effects of the aminoglycosides are dose-related, therefore, care must be taken with dosage, and, whenever possible, parenteral treatment should not exceed 7 days. Renal function should be assessed before starting an aminoglycoside and during treatment. If possible, dehydration should be corrected before starting an aminoglycoside. Auditory and vestibular function should also be monitored during treatment. In order to optimise the dose and avoid toxicity, serum-aminoglycoside concentrations should be monitored in patients receiving parenteral aminoglycosides (see also Serum Concentrations). Ototoxicity and nephrotoxicity occur most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.Aminoglycosides should be used with caution in those with conditions characterised by muscular weakness (avoid in myasthenia gravis). Aminoglycosides should preferably not be given with potentially ototoxic diuretics (e.g. furosemide); if concurrent use is unavoidable administration of the aminoglycoside and of the diuretic should be separated by as long a period as practicable. Interactions: Appendix 1 (aminoglycosides); interactions: Appendix 1 (aminoglycosides)Specific cautions for inhaled treatment\u00a0Other\r\ninhaled drugs should be administered before tobramycin. Measure lung\r\nfunction before and after initial dose of tobramycin and monitor for\r\nbronchospasm; if bronchospasm occurs in a patient not using a bronchodilator,\r\nrepeat test using bronchodilator. Monitor renal function before treatment\r\nand then annually. Severe haemoptysis\u2014risk of further haemorrhage.", "side-effects": "Side-effects\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nSide-effects\u00a0The important side-effects of the aminoglycosides are nephrotoxicity and irreversible ototoxicity (including vestibular and auditory damage). Rash occurs commonly with streptomycin, but less frequently with the other aminoglycosides. Rare side-effects include nausea, vomiting, antibiotic-associated colitis, peripheral neuropathy, electrolyte disturbances (notably hypomagnesaemia on prolonged therapy, but also hypocalcaemia and hypokalaemia), and stomatitis. Side-effects reported very rarely include blood disorders and CNS effects (including headache, encephalopathy, and convulsions). Aminoglycosides may impair neuromuscular transmission; large doses given during surgery have been responsible for a transient myasthenic syndrome in patients with normal neuromuscular function.; on inhalation, cough (more frequent by inhalation of powder),\r\nbronchospasm (see Cautions), dysphonia, taste disturbances, pharyngitis,\r\nmouth ulcers, salivary hypersecretion, laryngitis, haemoptysis, epistaxis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202815.htm", "doses": ["To avoid excessive dosage in obese patients, use ideal\r\nweight for height to calculate parenteral dose and monitor serum-tobramycin\r\nconcentration closely", "By intramuscular injection or by slow intravenous injection or by intravenous infusion, 3\u00a0mg/kg daily in divided\r\ndoses every 8 hours, see also notes above; in severe infections up\r\nto 5\u00a0mg/kg daily in divided doses every 6\u20138 hours (reduced to 3\u00a0mg/kg\r\nas soon as clinically indicated); child under 18 years see BNF for Children", "Urinary-tract infection, by intramuscular injection, 2\u20133\u00a0mg/kg daily as a single dose", "One-hour (\u2018peak\u2019) serum concentration should\r\nnot exceed 10\u00a0mg/litre; pre-dose (\u2018trough\u2019) concentration should be\r\nless than 2\u00a0mg/litre", "Chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis, by inhalation\r\nof nebulised solution, adult and child over 6 years, 300\u00a0mg every\r\n12 hours for 28 days, subsequent courses repeated after 28-day interval\r\nwithout tobramycin nebuliser solution", "By inhalation of powder, adult and child over 6 years, 112\u00a0mg every\r\n12 hours for 28 days, subsequent courses repeated after 28-day interval\r\nwithout tobramycin inhalation powder"], "pregnancy": "Pregnancy\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nPregnancy\u00a0There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin (section 5.1.9). The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential (if given, serum-aminoglycoside concentration monitoring is essential)."}, {"breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.3 Anti-infective eye preparations", "11.3.1 Antibacterials", "TOBRAMYCIN"], "indications": "Indications\u00a0\n(From 11.3.1 Antibacterials: British National Formulary)\n11.3.1 Antibacterials", "name": "TOBRAMYCIN - ANTIBACTERIALS", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/213676.htm", "doses": ["adult and child over 1 year, apply twice daily for 6\u20138 days;\r\nin severe infection, apply 4 times daily on the first day, then twice\r\ndaily for 5\u20137 days"]}, {"indications": "Indications\u00a0see under Gentamicin and notes above", "name": "TOBRAMYCIN Parenteral", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.4 Aminoglycosides", "TOBRAMYCIN", "Parenteral"], "cautions": "Cautions\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nCautions\u00a0The main side-effects of the aminoglycosides are dose-related, therefore, care must be taken with dosage, and, whenever possible, parenteral treatment should not exceed 7 days. Renal function should be assessed before starting an aminoglycoside and during treatment. If possible, dehydration should be corrected before starting an aminoglycoside. Auditory and vestibular function should also be monitored during treatment. In order to optimise the dose and avoid toxicity, serum-aminoglycoside concentrations should be monitored in patients receiving parenteral aminoglycosides (see also Serum Concentrations). Ototoxicity and nephrotoxicity occur most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.Aminoglycosides should be used with caution in those with conditions characterised by muscular weakness (avoid in myasthenia gravis). Aminoglycosides should preferably not be given with potentially ototoxic diuretics (e.g. furosemide); if concurrent use is unavoidable administration of the aminoglycoside and of the diuretic should be separated by as long a period as practicable. Interactions: Appendix 1 (aminoglycosides); interactions: Appendix 1 (aminoglycosides)Specific cautions for inhaled treatment\u00a0Other\r\ninhaled drugs should be administered before tobramycin. Measure lung\r\nfunction before and after initial dose of tobramycin and monitor for\r\nbronchospasm; if bronchospasm occurs in a patient not using a bronchodilator,\r\nrepeat test using bronchodilator. Monitor renal function before treatment\r\nand then annually. Severe haemoptysis\u2014risk of further haemorrhage.", "side-effects": "Side-effects\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nSide-effects\u00a0The important side-effects of the aminoglycosides are nephrotoxicity and irreversible ototoxicity (including vestibular and auditory damage). Rash occurs commonly with streptomycin, but less frequently with the other aminoglycosides. Rare side-effects include nausea, vomiting, antibiotic-associated colitis, peripheral neuropathy, electrolyte disturbances (notably hypomagnesaemia on prolonged therapy, but also hypocalcaemia and hypokalaemia), and stomatitis. Side-effects reported very rarely include blood disorders and CNS effects (including headache, encephalopathy, and convulsions). Aminoglycosides may impair neuromuscular transmission; large doses given during surgery have been responsible for a transient myasthenic syndrome in patients with normal neuromuscular function.; on inhalation, cough (more frequent by inhalation of powder),\r\nbronchospasm (see Cautions), dysphonia, taste disturbances, pharyngitis,\r\nmouth ulcers, salivary hypersecretion, laryngitis, haemoptysis, epistaxis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/37241.htm", "doses": ["To avoid excessive dosage in obese patients, use ideal\r\nweight for height to calculate parenteral dose and monitor serum-tobramycin\r\nconcentration closely", "By intramuscular injection or by slow intravenous injection or by intravenous infusion, 3\u00a0mg/kg daily in divided\r\ndoses every 8 hours, see also notes above; in severe infections up\r\nto 5\u00a0mg/kg daily in divided doses every 6\u20138 hours (reduced to 3\u00a0mg/kg\r\nas soon as clinically indicated); child under 18 years see BNF for Children", "Urinary-tract infection, by intramuscular injection, 2\u20133\u00a0mg/kg daily as a single dose", "One-hour (\u2018peak\u2019) serum concentration should\r\nnot exceed 10\u00a0mg/litre; pre-dose (\u2018trough\u2019) concentration should be\r\nless than 2\u00a0mg/litre", "Chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis, by inhalation\r\nof nebulised solution, adult and child over 6 years, 300\u00a0mg every\r\n12 hours for 28 days, subsequent courses repeated after 28-day interval\r\nwithout tobramycin nebuliser solution", "By inhalation of powder, adult and child over 6 years, 112\u00a0mg every\r\n12 hours for 28 days, subsequent courses repeated after 28-day interval\r\nwithout tobramycin inhalation powder", "Name[Tobramycin (Non-proprietary) ] Injection, tobramycin (as sulphate) 40\u00a0mg/mL, net price 1-mL (40-mg)\r\nvial = \u00a34.00, 2-mL (80-mg) vial = \u00a34.16, 6-mL (240-mg) vial = \u00a319.20"], "pregnancy": "Pregnancy\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nPregnancy\u00a0There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin (section 5.1.9). The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential (if given, serum-aminoglycoside concentration monitoring is essential)."}]